乳腺癌内科治疗新进展—— 胡夕春.ppt

乳腺癌内科治疗新进展 胡夕春 新药新方案 新理念 新药不良反应及处理 1.1白蛋白结合紫杉醇 (ABX) 1.2 EFECT: Evaluation of Treatment Options Following AI Failure EFECT: Similar TTP in Patients Treated With Fulvestrant or Exemestane EFECT: Patient Response and Study Conclusions Median duration of response to treatment with fulvestrant vs exemestane: 13.5 vs 9.8 months, respectively  Fulvestrant as effective and safe as exemestane in women with hormone receptor–positive breast cancer who have progressed on treatment with a nonsteroidal AI 1.3 Ixabepilone+Capecitabine vs Capecitabine Ixabepilone+Capecitabine vs Capecitabine Ixabepilone+Capecitabine vs Capecitabine 新药新方案 新理念 新药不良反应及处理 2.1 Lapatinib oral tyrosine kinase inhibitor of ErbB1 and ErbB2 Blocks signaling through EGFR and HER2 homodimers and heterodimers May also prevent signaling between ErbB1/ErbB2 and other ErbB family members Treatment Efficacy: Lapatinib Vs Lapatinib + Trastuzumab Progression-Free Survival: L Vs L+T EGF100151: Lapatinib + Capecitabine in Advanced Breast Cancer EGF100151: Lapatinib + Capecitabine in Advanced Breast Cancer (cont’d) Addition of lapatinib to capecitabine in women with treatment-refractory, advanced metastatic breast cancer associated with Longer time to progression 36.9 vs 19.7 wks (P = .00016) Longer progression-free survival 36.9 vs 17.9 wks (P = .000045) Fewer progressions or deaths 38% vs 48% Response (independent review) Overall: 22.5% vs 14.3% (P = .113) Phase III trial of Avastin plus docetaxel in first-line MBC (AVADO) Recruitment commenced March 2006 and completed in March 2007 Primary endpoint: PFS secondary endpoints: ORR, OS, safety, QoL Trial met primary endpoint; data will be presented mid-2008 Bevacizumab ± Paclitaxel for Locally Recurrent or Metastatic Disease Eastern Cooperative Oncology Group (ECOG) 2100 trial First planned interim analysis of randomized, first-line, phase 3 trial Bevacizumab ± Paclitaxel for Locally Recurrent or Metastatic Disease PFS significantly longer with combinat